VRDN
Viridian Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.92
−0.17%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 19.94x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 3.92x
- Price / sales
- 36.51x
- Price / cash flow
- -7.79x
Enterprise value
- Enterprise value
- $2.0B
- EV / sales
- 27.50x
- EV / EBITDA
- -5.31x
- EV / EBIT
- -4.83x
- Market cap
- $2.6B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026